Simvastatin

Generic Name
Simvastatin
Brand Names
Cholib, FloLipid, Simcor, Vytorin, Zocor
Drug Type
Small Molecule
Chemical Formula
C25H38O5
CAS Number
79902-63-9
Unique Ingredient Identifier
AGG2FN16EV
Background

Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...

Indication

Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...

Associated Conditions
Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event
Associated Therapies
-
Clinical Trials
Related News

Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Simvastatin
Drug: Rosuvastatin
Drug: MGL-3196
First Posted Date
2015-09-07
Last Posted Date
2022-09-02
Lead Sponsor
Madrigal Pharmaceuticals, Inc.
Target Recruit Count
25
Registration Number
NCT02542969
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

Effect of Simvastatin Withdrawal on Ocular Endothelial Function

First Posted Date
2015-08-26
Last Posted Date
2020-02-20
Lead Sponsor
Medical University of Vienna
Registration Number
NCT02533141
Locations
🇦🇹

Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria

Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure

Not Applicable
Completed
Conditions
Chronic Renal Failure
Hyperlipidemia
Hypertension
First Posted Date
2015-07-30
Last Posted Date
2023-03-16
Lead Sponsor
Mayo Clinic
Registration Number
NCT02511418

Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

First Posted Date
2015-06-19
Last Posted Date
2022-03-28
Lead Sponsor
Sanofi
Target Recruit Count
998
Registration Number
NCT02476006
Locations
🇦🇹

Investigational Site Number 040001, Graz, Austria

🇦🇹

Investigational Site Number 040002, Wien, Austria

🇦🇹

Investigational Site Number 040010, Wien, Austria

and more 150 locations

Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Type 2 Diabetes Mellitus
Interventions
Drug: PEX168
Drug: Simvastatin
First Posted Date
2015-05-19
Last Posted Date
2017-01-24
Lead Sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Target Recruit Count
16
Registration Number
NCT02447601
Locations
🇨🇳

Shanghai Mental Health Center (SMHC), Shanghai, Shanghai, China

Trial of Simvastatin for the Treatment of Severe Asthma

Phase 2
Withdrawn
Conditions
Severe Asthma
Interventions
Other: Placebo
Drug: Simvastatin
First Posted Date
2015-05-05
Last Posted Date
2017-09-26
Lead Sponsor
University of California, Davis
Registration Number
NCT02433535
Locations
🇺🇸

CTSC Clinical Research Center, Sacramento, California, United States

Cilostazol-Simvastatin Drug Interaction Study

First Posted Date
2015-04-30
Last Posted Date
2015-05-01
Lead Sponsor
Ajou University School of Medicine
Target Recruit Count
20
Registration Number
NCT02431013
Locations
🇰🇷

Ajou University Medical Center, Suwon, Gyeonggi, Korea, Republic of

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

First Posted Date
2015-04-02
Last Posted Date
2019-11-04
Lead Sponsor
AstraZeneca
Target Recruit Count
82
Registration Number
NCT02406261
Locations
🇺🇸

Covance Inc, Dallas, Texas, United States

Trial to Evaluate the Efficacy of Simvastatin for Smoking Cessation

Phase 2
Completed
Conditions
Smoking Cessation
Interventions
Drug: Placebo
Drug: simvastatin
First Posted Date
2015-03-26
Last Posted Date
2020-04-13
Lead Sponsor
Poitiers University Hospital
Target Recruit Count
124
Registration Number
NCT02399709
Locations
🇫🇷

Poitiers University Hospital, Poitiers, France

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

First Posted Date
2015-03-18
Last Posted Date
2020-04-03
Lead Sponsor
Emory University
Target Recruit Count
13
Registration Number
NCT02390843
Locations
🇺🇸

Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy